A randomized clinical trial indicated that add-on baclofen may be of benefit to patients on adequate doses of proton pump inhibitors (PPI) with refractory gastroesophageal reflux disease (GERD). However, the benefit was limited to a subset of patients with positive symptom association probability (SAP), which was calculated using 24-hour combined multichannel intraluminal impedance and pH monitoring (24h pH-MII).
Baclofen shows limited role in GERD (MDedge)
0![Baclofen shows limited role in GERD (MDedge)](https://scopeforward.com/wp-content/uploads/2022/08/GERD_web.jpg)
copyright nebari/Thinkstock